Loading...
•
Dec 31, 2025
Sionna Therapeutics Inc Q4 2025 Earnings Report
Sionna Therapeutics Inc reported fourth quarter 2025 financial results with increased operating expenses and a higher net loss year-over-year.
Key Takeaways
For Q4 2025, Sionna reported a net loss of 20440000 driven by research and development expenses of 15168000 and general and administrative expenses of 8444000. The company ended the quarter with 310302000 in cash, cash equivalents and marketable securities.
Net loss for Q4 2025 was 20440000 compared to 15848000 in Q4 2024.
Research and development expenses increased to 15168000.
General and administrative expenses rose to 8444000.
Cash, cash equivalents and marketable securities totaled 310302000 at quarter end.
Forward Guidance
Sionna expects its current cash position to fund operations into 2028 while advancing its Phase 2a and Phase 1 clinical programs.
Positive Outlook
- Cash runway expected into 2028.
- Phase 2a PreciSION CF trial topline data anticipated mid-2026.
- Phase 1 dual combination trial topline data anticipated mid-2026.
- Positive Phase 1 data for SION-719 and SION-451 previously reported.
- Strong balance sheet following IPO.
Challenges Ahead
- Net loss increased year-over-year.
- Operating expenses continue to rise with pipeline advancement.
- No product revenue generated.
- Clinical-stage company with development risk.
- Dependence on successful trial outcomes.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...